Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923193 · ClinicalTrials.gov registry record · NA
Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)
A NA study, sponsored by Shockwave Medical.
- Completed
- Registry status
- NA
- Development phase
- 306
- Enrollment target
NCT02923193: Completed NA study, sponsored by Shockwave Medical.
NCT02923193 is a NA study that has completed, run by Shockwave Medical. The registered enrollment target is 306 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02923193, a NA study, has completed, sponsored by Shockwave Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 306 participants
- Enrollment target
Study Summary
Shockwave Medical Inc. intends to conduct a prospective, multi-center, single blind, randomized (1:1) study of Lithoplasty treatment used in combination with DCB versus standard balloon angioplasty used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries. Assuming that roughly 15% of the subjects will be lost-to-follow-up, a total of up to 400 subjects (200 per treatment arm) will be enrolled in the study at up to 60 sites in Europe, the United States and New Zealand. In addition to the randomized study, an observational study of subjects who do not meet the inclusion/exclusion criteria for the randomized study will be conducted. The objective of the observational study is to assess the real-world acute performance of the Shockwave Medical Peripheral Lithoplasty System in the treatment of calcified, stenotic, peripheral arteries. The observational study is a prospective, multi-center, single arm observational study for subjects who do not meet the inclusion/exclusion criteria of the randomized study. A maximum of 1500 subjects at the same 60 sites will be enrolled in the observational study. Once enrollment in the randomized portion of the study is complete, subjects may continue to be enrolled in the observational study provided they meet OS eligibility criteria. Results for the observational study will be reported in a separate record under NCT05881421.
Primary Outcome
Procedural success is defined as residual stenosis ≤30% without flow-limiting dissection (≥ grade D) prior to DCB or stenting by angiographic core lab.
Interventions
- DEVICE Shockwave Lithoplasty® Peripheral Lithoplasty System
- DRUG Medtronic IN.PACT (DCB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2022-06-02 |
| Phase | NA |
What the finished NCT02923193 record still lists
NCT02923193 is an interventional study that assigns participants to a tested intervention. The registered 306 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Shockwave Lithoplasty® Peripheral Lithoplasty System is the first listed.
NCT02923193 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02923193 about?
NCT02923193 is a clinical study titled "Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)". Shockwave Medical Inc. intends to conduct a prospective, multi-center, single blind, randomized (1:1) study of Lithoplasty treatment used in combination with DCB versus standard balloon angioplasty used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries. Assumi...
What is the current status of trial NCT02923193?
This trial is currently completed. It is a NA study. The enrollment target is 306 participants. The study started on 2017-02-22. Estimated completion is 2022-06-02.
What interventions are being tested in trial NCT02923193?
The interventions under investigation include: Shockwave Lithoplasty® Peripheral Lithoplasty System (DEVICE), Medtronic IN.PACT (DCB) (DRUG).
Who is sponsoring clinical trial NCT02923193?
This trial is sponsored by Shockwave Medical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02923193's enrollment target sits among peer trials
306 324th of 2000 higher than 1,674 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05078970 · 306 participants · NA
Advancing Suicide Intervention Strategies for Teens During High Risk Periods
- NCT05843695 · 306 participants · NA
Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety
- NCT06057337 · 306 participants · NA
Families With Pride ("Familias Con Orgullo").
- NCT06498635 · 306 participants · Phase 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI